₹ 830.67 Cr
2.34%
S&P BSE Healthcare
INF179KC1HL7
100.0
100.0
0
Dhruv Muchhal, Nikhil Mathur
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
HDFC Pharma and Healthcare Fund - Growth Option | - | - | - |
S&P BSE Healthcare TRI | 52.62 | 13.64 | 22.27 |
Equity
Debt
Others
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Company | Holdings (%) |
---|---|
Sun Pharmaceutical Industries Ltd. | 13.51 |
Cipla Ltd. | 7.86 |
Lupin Ltd. | 6.34 |
Ajanta Pharma Ltd. | 4.97 |
Max Healthcare Institute Ltd. | 4.18 |
Torrent Pharmaceuticals Ltd. | 4.11 |
Krishna Institute of Medical Sciences Ltd | 3.93 |
Gland Pharma Ltd. | 3.77 |
Aurobindo Pharma Ltd. | 3.32 |
Alkem Laboratories Ltd. | 3.25 |
Sector | Holdings (%) |
---|---|
Healthcare | 95.76 |
Others | 1.81 |
Chemicals | 1.44 |
Services | 0.99 |
Scheme Name | 5Y (%) |
---|---|
HDFC Pharma and Healthcare Fund Gr | 0.0 |
ICICI Pru Pharma Healthcare and Diagnostics PHD Fund Cum | 25.77 |
ABSL Pharma and Healthcare Reg Gr | 0.0 |
Tata India Pharma & Healthcare Reg Gr | 23.56 |
SBI HEALTHCARE Opportunities Reg Gr | 24.87 |
Nippon India Pharma Fund Gr Gr | 24.41 |
UTI Healthcare Reg Gr | 22.44 |
DSP Healthcare Reg Gr | 27.19 |
Mirae Asset Healthcare Reg Gr | 25.04 |
LIC MF Healthcare Fund Reg Gr | 19.52 |